Literature DB >> 15852368

Cross-sectional survey of Parkinson's disease and parkinsonism in a rural area of the United Kingdom.

Peter Hobson1, John Gallacher, Jolyon Meara.   

Abstract

The objective of this study was to estimate the crude and standardized age/sex-adjusted prevalence rates of parkinsonism and Parkinson's disease (PD) in a rural area of North Wales. Cases of PD and parkinsonism in a geographically defined rural area of North Wales were ascertained from the prescription of antiparkinsonian medication in primary care, hospital records, attendance at general medical outpatient clinics and at a specialist movement disorder clinic. In this population, the crude prevalence of clinically probable/possible PD was 144 per 1000,000 (95% confidence interval [CI], 120-173) and for parkinsonism 169 per 100,000 (95% CI, 143-201). When adjusted to the UK population, the prevalence for clinically probable PD was 105 per 100,000 (95% CI, 85-124) and for parkinsonism 122 per 100,000 (95% CI, 102-143). Age- and sex-adjusted standardized rates indicate that regional variations in PD and parkinsonism may exist in the United Kingdom. There are several possible reasons for this, although methodological differences between studies may be the most likely explanations for the present findings. Copyright 2005 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15852368     DOI: 10.1002/mds.20489

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

1.  Decreased ventral striatal activity with impulse control disorders in Parkinson's disease.

Authors:  Hengyi Rao; Eugenia Mamikonyan; John A Detre; Andrew D Siderowf; Matthew B Stern; Marc N Potenza; Daniel Weintraub
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

Review 2.  Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers.

Authors:  Alexander I Tröster
Journal:  Neuropsychol Rev       Date:  2008-03-06       Impact factor: 7.444

3.  Drug-induced parkinsonism.

Authors:  Frandy Susatia; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

4.  Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease.

Authors:  Rakhee Krishna; Manal Ali; Ahmed A Moustafa
Journal:  Front Aging Neurosci       Date:  2014-07-25       Impact factor: 5.750

5.  Medium-to-high prevalence of screening-detected parkinsonism in the urban area of Tehran, Iran: data from a community-based door-to-door study.

Authors:  Seyed-Mohammad Fereshtehnejad; Mahdiyeh Shafieesabet; Arash Rahmani; Ahmad Delbari; Johan Lökk
Journal:  Neuropsychiatr Dis Treat       Date:  2015-02-05       Impact factor: 2.570

Review 6.  Parkinson's Disease and Cognitive Impairment.

Authors:  Yang Yang; Bei-Sha Tang; Ji-Feng Guo
Journal:  Parkinsons Dis       Date:  2016-12-12

7.  Epidemiology of Parkinson's disease.

Authors:  Meike Kasten; Annabel Chade; Caroline M Tanner
Journal:  Handb Clin Neurol       Date:  2007

Review 8.  Parkinson's Disease in Sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care.

Authors:  Uduak Williams; Oliver Bandmann; Richard Walker
Journal:  J Mov Disord       Date:  2018-05-30

Review 9.  Dementia with Parkinson disease: Clinical diagnosis, neuropsychological aspects and treatment.

Authors:  Jorge Lorenzo Otero
Journal:  Dement Neuropsychol       Date:  2008 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.